New partners for Phase 2 trial of next-gen lithium therapy AL001
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for Alzheimer’s dementia.| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
